CN1265786C - 式ⅰ的化合物和紫杉醇在制备用于治疗癌症疾病的药物中的用途 - Google Patents

式ⅰ的化合物和紫杉醇在制备用于治疗癌症疾病的药物中的用途 Download PDF

Info

Publication number
CN1265786C
CN1265786C CNB028047516A CN02804751A CN1265786C CN 1265786 C CN1265786 C CN 1265786C CN B028047516 A CNB028047516 A CN B028047516A CN 02804751 A CN02804751 A CN 02804751A CN 1265786 C CN1265786 C CN 1265786C
Authority
CN
China
Prior art keywords
compound
formula
paclitaxel
cycle
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028047516A
Other languages
English (en)
Chinese (zh)
Other versions
CN1491126A (zh
Inventor
L·H·布赖默
K·德林拉
U·H·德林拉
S·里特兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1491126A publication Critical patent/CN1491126A/zh
Application granted granted Critical
Publication of CN1265786C publication Critical patent/CN1265786C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB028047516A 2001-02-09 2002-02-01 式ⅰ的化合物和紫杉醇在制备用于治疗癌症疾病的药物中的用途 Expired - Lifetime CN1265786C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26787401P 2001-02-09 2001-02-09
US06/267,874 2001-02-09

Publications (2)

Publication Number Publication Date
CN1491126A CN1491126A (zh) 2004-04-21
CN1265786C true CN1265786C (zh) 2006-07-26

Family

ID=23020488

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028047516A Expired - Lifetime CN1265786C (zh) 2001-02-09 2002-02-01 式ⅰ的化合物和紫杉醇在制备用于治疗癌症疾病的药物中的用途

Country Status (17)

Country Link
US (1) US6548531B2 (https=)
EP (1) EP1359979B1 (https=)
JP (1) JP4128872B2 (https=)
KR (1) KR100542069B1 (https=)
CN (1) CN1265786C (https=)
AR (2) AR035429A1 (https=)
AT (1) ATE324145T1 (https=)
AU (1) AU2002246080B2 (https=)
BR (1) BR0206954A (https=)
CA (1) CA2435921C (https=)
DE (1) DE60210926T2 (https=)
DK (1) DK1359979T3 (https=)
ES (1) ES2261648T3 (https=)
MX (1) MXPA03007036A (https=)
PT (1) PT1359979E (https=)
WO (1) WO2002064214A2 (https=)
ZA (1) ZA200305967B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
JP2004532245A (ja) * 2001-05-15 2004-10-21 ページ ダブル フォーク 癌を治療するための生体影響性化合物の標的送達
JP2004537515A (ja) * 2001-05-15 2004-12-16 フォーク ファーマシューティカルス，インク． ウィルス感染症治療用薬物のターゲッティング送達
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
WO2018092020A1 (en) 2016-11-15 2018-05-24 Novartis Ag Dose and regimen for hdm2-p53 interaction inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
US6080777A (en) * 1992-01-31 2000-06-27 The Trustees Of Columbia University In The City Of New York Taxol as a radiation sensitizer
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
CA2140653A1 (en) * 1992-08-12 1994-03-03 Irene Abraham Protein kinase inhibitors and related compounds combined with taxol
PT1064279E (pt) 1998-03-17 2003-10-31 Hoffmann La Roche Bisindolilmaleimidas substituidas para a inibicao da proliferacao celular
WO1999055321A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression

Also Published As

Publication number Publication date
WO2002064214A3 (en) 2003-05-30
AU2002246080C1 (en) 2002-08-28
ZA200305967B (en) 2005-01-26
CN1491126A (zh) 2004-04-21
ATE324145T1 (de) 2006-05-15
DK1359979T3 (da) 2006-08-28
AR098745A2 (es) 2016-06-08
MXPA03007036A (es) 2003-11-18
EP1359979A2 (en) 2003-11-12
PT1359979E (pt) 2006-08-31
WO2002064214A8 (en) 2004-02-19
BR0206954A (pt) 2004-02-25
US20020156118A1 (en) 2002-10-24
JP2004517961A (ja) 2004-06-17
KR20040025894A (ko) 2004-03-26
US6548531B2 (en) 2003-04-15
WO2002064214A2 (en) 2002-08-22
JP4128872B2 (ja) 2008-07-30
AR035429A1 (es) 2004-05-26
EP1359979B1 (en) 2006-04-26
CA2435921C (en) 2009-12-22
DE60210926D1 (de) 2006-06-01
ES2261648T3 (es) 2006-11-16
AU2002246080B2 (en) 2006-08-10
CA2435921A1 (en) 2002-08-22
KR100542069B1 (ko) 2006-01-11
DE60210926T2 (de) 2007-01-11

Similar Documents

Publication Publication Date Title
CN1265786C (zh) 式ⅰ的化合物和紫杉醇在制备用于治疗癌症疾病的药物中的用途
CN1703223A (zh) 喹唑啉衍生物 z d 6 4 7 4组合吉西他滨并任选组合电离辐射在治疗与血管生成和 /或血管通透性增加相关的疾病中的用途
JP2003533485A5 (https=)
JP6656397B2 (ja) 抗腫瘍薬物の効果を有する併用薬物
AU2002246080A1 (en) Method for Cancer Therapy
CN1181819C (zh) 使用五氟苯磺酰胺的综合疗法
CN1575168A (zh) 包含选择性环加氧酶－2抑制剂的组合
CN1787814A (zh) 增加抗癌药剂抗肿瘤活性的方法
JP2022542725A (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
CN101181230A (zh) 一种治疗实体肿瘤的雌二醇氮芥缓释植入剂
WO2024183692A1 (zh) 预防和/或治疗化疗药物损伤消化道的保护剂及其应用
CN117357534A (zh) 包含维甲酸的药物组合物在制备治疗肝细胞癌伴腹腔转移的药物中的用途
CN111407748B (zh) 酪醇在制备治疗脑胶质瘤的药物中的应用
CN101181232B (zh) 一种治疗实体肿瘤的马赛替尼缓释植入剂
CN1867344A (zh) 含有氧代铂、其盐和衍生物的药物组合物
CN113786491A (zh) 一种含汉防己甲素、二氢槲皮素或槲皮素的抗肿瘤联用制剂
CN1102047C (zh) 一种新的肿瘤细胞多药耐药性逆转剂
CN101185629A (zh) 一种治疗实体肿瘤的地西他滨缓释剂
CN1187047C (zh) 地非三唑在制备治疗恶性肿瘤疾病药剂中的应用
CN112294811A (zh) 一种治疗胶质瘤的混合制剂
CN1496269A (zh) 含有p43蛋白和紫杉醇的治疗癌症的药用性合成物以及应用其的治疗方法和用途
CN1853625A (zh) 木犀草素与一种铂类化疗药物的联合
JP2006518355A (ja) インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法
CN120208912A (zh) 类天然二芳基丙烷二聚体化合物及其在制备治疗癌症药物中的应用
CN101181234B (zh) 一种治疗实体肿瘤的利特替尼缓释植入剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20060726